International Journal of Clinical Case Reports 2024, Vol.14, No.4, 189-201 http://medscipublisher.com/index.php/ijccr 200 Diaz-Montero C., Rini B., and Finke J., 2020, The immunology of renal cell carcinoma, Nature Reviews Nephrology, 16: 721-735. https://doi.org/10.1038/s41581-020-0316-3 Dougan M., 2017, Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract, Frontiers in Immunology, 8: 1547. https://doi.org/10.3389/fimmu.2017.01547 PMID: 29230210 PMCID: PMC5715331 Feng M., Jiang W., Kim B., Zhang C., Fu Y., and Weissman I., 2019, Phagocytosis checkpoints as new targets for cancer immunotherapy, Nature Reviews Cancer, 19: 568-586. https://doi.org/10.1038/s41568-019-0183-z Flippot R., Escudier B., and Albiges L., 2018, Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma, Drugs, 78: 1443-1457. https://doi.org/10.1007/s40265-018-0970-y PMID: 30187355 Goebeler M., and Bargou R., 2020, T cell-engaging therapies - BiTEs and beyond, Nature Reviews Clinical Oncology, 17(7): 418-434. https://doi.org/10.1038/s41571-020-0347-5 PMID: 32242094 Henau O.de., Rausch M., Winkler D., Liu C., Cymerman D.H., Budhu S., Ghosh A., Pink M., Tchaicha M., Douglas M., Tibbitts T., Sharma S., Proctor J., Kosmider N., White K.F., Stern H., Soglia J., Adams J., Palombella V., and McGovern K., 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells, Nature, 539: 443-447. https://doi.org/10.1038/nature20554 PMID: 27828943 PMCID: PMC5634331 Lee C.H., Dinatale R., Chowell D., Krishna C., Makarov V., Valero C., Vuong L., Weiss K., Hoen D.R., Morris L., Kotecha R., and Chan T., 2021, High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab, Molecular Cancer Research, 19: 1510-1521. https://doi.org/10.1158/1541-7786.MCR-21-0053 PMID: 34039647 PMCID: PMC8419018 Li H., Bullock K., Gurjao C., Braun D., Shukla S., Bossé D., Lalani A., Gopal S., Jin C., Horak C., Wind-Rotolo M., Signoretti S., McDermott D., Freeman G., Van Allen E.V., Schreiber S., Hodi F.S., Sellers W., and Garraway L., 2019, Metabolomic adaptations and correlates of survival to immune checkpoint blockade, Nature Communications, 10(1): 4346. https://doi.org/10.1038/s41467-019-12361-9 PMID: 31554815 PMCID: PMC6761178 Li J., Chen Y., Li Y., Liu N., and Ma J., 2021, Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades, Molecular Cancer, 20(1): 27. https://doi.org/10.1186/s12943-021-01317-7 PMID: 33541368 PMCID: PMC7863268 Martínez-Sabadell A., Arenas E.J., Rius Ruiz I., Alonso M.R., Escorihuela M., Luque A., Fajardo C.A., Gros A., and Arribas J., 2022, Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation, Cancer Research, 82 (12_Supplement): 3970. https://doi.org/10.1158/1538-7445.AM2022-3970 Massari F., Rizzo A., Mollica V., Rosellini M., Marchetti A., Ardizzoni A., and Santoni M., 2021, Immune-based combinations for the treatment of metastatic renal cell carcinoma: au meta-analysis of randomised clinical trials, European Journal of Cancer, 154: 120-127. https://doi.org/10.1016/j.ejca.2021.06.015 PMID: 34265504 Meng L., Collier K.A., Wang P., Li Z., Monk P., Mortazavi A., Hu Z., Spakowicz D.J., Zheng L., and Yang Y., 2023, Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma, Cells, 13(1): 34. https://doi.org/10.3390/cells13010034 PMID: 38201238 PMCID: PMC10777977 Miao D., Margolis C., Gao W., Voss M., Li W., Martini D., Norton C.K., Bossé D., Wankowicz S.A.M., Cullen D., Horak C., Wind-Rotolo M., Tracy A., Giannakis M., Hodi F., Drake C., Ball M.W., Allaf M., Snyder A., Hellmann M.D., Ho T., Motzer R.J., Signoretti S., Kaelin W.J., Choueir T.K., and Van Allen E.V., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, 359(6377): 801-806. https://doi.org/10.1126/science.aan5951 PMID: 38201238 Moreira M., Pobel C., Epaillard N., Simonaggio A., Oudard S., and Vano Y., 2020, Resistance to cancer immunotherapy in metastatic renal cell carcinoma, Cancer Drug Resistance, 3(3): 454-471. https://doi.org/10.20517/cdr.2020.16 PMID: 35582435 PMCID: PMC8992500 Murakami N., Borges T., Yamashita M., and Riella L., 2016, Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma, Clinical Kidney Journal, 9: 411-417. https://doi.org/10.1093/ckj/sfw024 PMID: 27274826 PMCID: PMC4886917
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==